← All trials
NCT06093308
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2023
- Primary completion
- Aug 25, 2023
- Completion date
- Aug 25, 2023
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Sponsor GmbHCollaborator
- Government of ChinaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.